Anti-VEGF therapy and the retina: An update

Journal of Ophthalmology

Volumn 2015, Issue , 2015, Pages

  Tah, Vikas ^a   Orlans, Harry O ^b   Hyer, Jonathan ^b   Casswell, Edward ^b   Din, Nizar ^b   Sri Shanmuganathan, Vishnu ^c   Ramskold, Louise ^b   Pasu, Saruban ^b  

^a ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941652007     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2015/627674     Document Type: Review

References (87)

1. M. Rajappa, P. Saxena, and J. Kaur, "Ocular angiogenesis:mechanisms and recent advances in therapy. Advances in Clinical Chemistry, vol. 50, pp. 103-121, 2010.
2. PMLive, "Top Pharma list, "November 2014, http://www.pmlive .com/top pharma list/Top 50 pharmaceutical products by global sales
3. J. G. Arroyo, "Towards a rational approach to combination therapy for neovascular age related macular degeneration. The British Journal of Ophthalmology, vol. 91, no. 2, pp. 130-131, 2007.
4. J.W. Miller, A. P. Adamis, D. T. Shima, et al, "Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. American Journal of Pathology, vol. 145, no. 3, pp. 574-584, 1994.
5. L. P. Aiello, R. L. Avery, P.G. Arrigg, et al, "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine, vol. 331, no. 22, pp. 1480-1487, 1994.
6. M. S. Gordon, K. Margolin, M. Talpaz, et al, "Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Journal of Clinical Oncology, vol. 19, no. 3, pp. 843-850, 2001.
7. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr, M. Feinsod, and D. R. Guyer, "Pegaptanib for neovascular agerelated macular degeneration. The New England Journal of Medicine, vol. 351, no. 27, pp. 2805-2816, 2004.
8. A. J. Augustin, "Change of treatment paradigms for wet agerelated macular degeneration. Clinical & Experimental Immunology, vol. 121, pp. 458-465, 2000.
9. P. J. Rosenfeld, A. A. Moshfeghi, and C. A. Puliafito, "Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 4, pp. 331-335, 2005.
10. P. J. Rosenfeld, D. M. Brown, J. S. Heier, et al, "Ranibizumab for neovascular age-related macular degeneration. The New England Journal ofMedicine, vol. 355, no. 14, pp. 1419-1431, 2006.
11. D. M. Brown, P. K. Kaiser, M. Michels, et al, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine, vol. 355, no. 14, pp. 1432-1444, 2006.
12. M. W. Stewart, P. J. Rosenfeld, F. M. Penha, et al, "Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina, vol. 32, no. 3, pp. 434-457, 2012.
13. Centers for Disease Control and Prevention, "Blindness caused by diabetes-Massachusetts, 1987-1994. The Journal of the American Medical Association, vol. 276, no. 23, pp. 1865-1866, 1996.
14. E. Prokofyeva and E. Zrenner, "Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research, vol. 47, no. 4, pp. 171-188, 2012.
15. J. A. Ford, N. Lois, P. Royle, C. Clar, D. Shyangdan, and N. Waugh, "Current treatments in diabetic macular oedema: systematic review and meta-Analysis. British Medical Journal Open, vol. 3, no. 2, Article ID e002269, 2013.
16. National Institute for Health and Clinical Excellence (NICE), "Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237). April 2013, http://www.nice.org.uk/guidance/ta274.
17. P. Mitchell, F. Bandello, U. Schmidt-Erfurth, et al, "The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology, vol. 118, no. 4, pp. 615-625, 2011.
18. Diabetic Retinopathy Clinical ResearchNetwork, "Expanded 2-year follow-up of Ranibizumab plus prompt or deferred laser or Triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology, vol. 118, no. 4, pp. 609-614, 2011.
19. P. Massin, F. Bandello, J. G. Garweg, et al, "Safety and efficacy of ranibizumab in diabeticmacular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care, vol. 33, no. 11, pp. 2399-2405, 2010.
20. D. V. Do, Q. D. Nguyen, A. A. Khwaja, et al, "Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology, vol. 131, no. 2, pp. 139-145, 2013.
21. D. V. Do, J. S. Heier, S. M. Shah, et al, "Two-year results of the READ 2 study: ranibizumab for edema of the macula in diabetes. Investigative Ophthalmology & Visual Science, vol. 51, no. 5, pp. 5842-5847, 2010.
22. RISE and RIDE Research Group, "Ranibizumab for diabetic macular edema: results from2 phase III randomized trials: RISE and RIDE. Ophthalmology, vol. 119, no. 4, pp. 789-801, 2012.
23. Decision Support Unit, "Bevacizumab in eye conditions: issues related to quality, use, efficacy and safety. 2012, http:// www.nicedsu.org.uk/Bevacizumab%20report%20-%20NICE% 20published%20version%2011.04.13.pdf
24. R. Rajendram, S. Fraser-Bell, A. Kaines, et al, "A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-Month data: report 3. Archives of Ophthalmology, vol. 130, no. 8, pp. 972-979, 2012.
25. D. V. Do, Q. D. Nguyen, D. Boyer, et al, "One-year outcomes of the da Vinci study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology, vol. 119, no. 8, pp. 1658-1665, 2012.
26. J.-F. Korobelnik, D. V. Do, U. Schmidt-Erfurth, et al, "Intravitreal aflibercept for diabetic macular edema. Ophthalmology, vol. 121, no. 11, pp. 2247-2254, 2014.
27. The Diabetic Retinopathy Clinical Research Network, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, "TheNew England Journal ofMedicine, vol. 372, pp. 1193-1203, 2015.
28. National Institute forHealth and Care Excellence (NICE), "Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). 2013, http://www.nice.org.uk/guidance/ta301/.
29. G. Virgili, M. Parravano, F. Menchini, and J. R. Evans, "Anti-vascular endothelial growth factor for diabetic macular oedema. The Cochrane Database of Systematic Reviews, vol. 10, 2014.
30. S. Goyal, M. Lavalley, and M. L. Subramanian, "Meta-Analysis and review on the effect of bevacizumab in diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 1, pp. 15-27, 2011.
31. Royal College of Ophthalmology, "Diabetic Retinopathy Guidelines. July 2013, https://www.rcophth.ac.uk/wp-content/ uploads/2014/12/2013-SCI-301-FINAL-DR-GUIDELINES-DEC-2012-updated-July-2013.pdf
32. Q. T. Ho and C. J. Kuo, "Vascular endothelial growth factor: biology and therapeutic applications, "The International Journal of Biochemistry & Cell Biology, vol. 39, no. 7-8, pp. 1349-1357, 2007.
33. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, "Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: twoyear results of theANCHOR Study. Ophthalmology, vol. 116, no. 1, pp. 57.e5-65.e5, 2009.
34. P. Abraham, H. Yue, and L. Wilson, "Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-relatedmacular degeneration: PIER study year 2, "American Journal of Ophthalmology, vol. 150, no. 3, pp. 315.e1-324.e1, 2010.
35. U. Schmidt-Erfurth, B. Eldem, R. Guymer, et al, "Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study. Ophthalmology, vol. 118, no. 5, pp. 831-839, 2011.
36. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung, et al, "A variabledosing regimen with intravitreal ranibizumab for neovascular age-relatedmacular degeneration: year 2 of the PrONTOStudy. American Journal of Ophthalmology, vol. 148, no. 1, pp. 43-58.e1, 2009.
37. F. G. Holz, W. Amoaku, J. Donate, et al, "Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology, vol. 118, no. 4, pp. 663-671, 2011.
38. B. G. Busbee, A. C. Ho, D. M. Brown, et al, "Twelve-month efficacy and safety of 0.5 mg or 2.0mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology, vol. 120, no. 5, pp. 1046-1056, 2013.
39. M. Engelbert, S. A. Zweifel, and K. B. Freund, "Long-Term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified 'treat and extend' dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina, vol. 30, no. 9, pp. 1368-1375, 2010.
40. M. Engelbert, S. A. Zweifel, and K. B. Freund, "treat and extend' dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina, vol. 29, no. 10, pp. 1424-1431, 2009.
41. D. F. Martin, M. G. Maguire, G. S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine, vol. 364, no. 20, pp. 1897-1908, 2011.
42. U. Chakravarthy, S. P. Harding, C. A. Rogers, et al, "Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet, vol. 382, no. 9900, pp. 1258-1267, 2013.
43. U. Schmidt-Erfurth, P. K. Kaiser, J.-F. Korobelnik, et al, "Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology, vol. 121, no. 1, pp. 193-201, 2014.
44. J. S. Heier, D. M. Brown, V. Chong, et al, "Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology, vol. 119, pp. 2537-2548, 2012.
45. M. J. Tolentino, A. Dennrick, E. John, and M. S. Tolentino, "Drugs in phase II clinical trials for the treatment of agerelated macular degeneration. Expert Opinion on Investigational Drugs, vol. 24, no. 2, pp. 183-199, 2015.
46. P. U. Dugel, "Phase 2b clinical trial of Fovista anti-PDGF therapy (1.5mg) in patients with neovascular age-related macular degeneration (wet AMO). in Proceedings of the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting, American Academy of Ophthalmology (AAO), November 2012.
47. D. H. Orth and A. Patz, "Retinal branch vein occlusion. Survey of Ophthalmology, vol. 22, no. 6, pp. 357-376, 1978.
48. The Branch Vein Occlusion Study Group, "Argon laser photocoagulation for macular edema in branch vein occlusion. American Journal of Ophthalmology, vol. 98, no. 3, pp. 271-282, 1984.
49. G. Coscas, A. Loewenstein, A. Augustin, et al, "Management of retinal vein occlusion-consensus document. Ophthalmologica, vol. 226, no. 1, pp. 4-28, 2011.
50. M. Laouri, E. Chen, M. Looman, and M. Gallagher, "The burden of disease of retinal vein occlusion: review of the literature. Eye, vol. 25, no. 8, pp. 981-988, 2011.
51. J.-D. Ho, C.-Y. Tsai, S.-W. Liou, R. J.-F. Tsai, and H.-C. Lin, "Seasonal variations in the occurrence of retinal vein occlusion: a five-year nationwide population-based study from Taiwan. American Journal of Ophthalmology, vol. 145, no. 4, pp. 722.3-728.e3, 2008.
52. R. Klein, S. E. Moss, S. M. Meuer, and B. E. K. Klein, "The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Archives of Ophthalmology, vol. 126, no. 4, pp. 513-518, 2008.
53. J. Rehak and M. Rehak, "Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Current Eye Research, vol. 33, no. 2, pp. 111-131, 2008.
54. J. G. Haymore and L. J. Mejico, "Retinal vascular occlusion syndromes. International Ophthalmology Clinics, vol. 49, no. 3, pp. 63-79, 2009.
55. C. Kaur, W. S. Foulds, and E. A. Ling, "Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Progress in Retinal and Eye Research, vol. 27, no. 6, pp. 622-647, 2008.
56. D. M. Brown, P. A. Campochiaro, R. B. Bhisitkul, et al, "Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology, vol. 118, no. 8, pp. 1594-1602, 2011.
57. D. M. Brown, P. A. Campochiaro, R. P. Singh, et al, "Ranibizumab for macular edema following central retinal vein occlusion: six month primary end point results of a phase III study. Ophthalmology, vol. 117, no. 6, pp. 1124-1133, 2010.
58. D. Boyer, J. Heier, D. M. Brown, et al, "Vascular endothelial growth factor Trap-Eye formacular edema secondary to central retinal vein occlusion: Six-month results of the phase 3 COPERNICUS Study. Ophthalmology, vol. 119, no. 5, pp. 1024-1032, 2012.
59. D. M. Brown, "Intravitreal aflibercept injection of central retinal vein occlusions: 2-year results from the COPERNICUS Study. American Academy of Ophthalmology, vol. 155, no. 3, pp. 429-437, 2012.
60. T. Y. Wong, A. Ferreira, R. Hughes, G. Carter, and P. Mitchell, "Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. American Journal of Ophthalmology, vol. 157, no. 1, pp. 9.e12-25.e12, 2014.
61. J. Kanski, Clinical Ophthalmology: A Systematic Approach, Butterworth-Heinemann, 7th edition, 2011.
62. N. Leveziel, Y. Yu, R. Reynolds, et al, "Genetic factors for choroidal neovascularization associated with highmyopia. Investigative Ophthalmology and Visual Science, vol. 53, no. 8, pp. 5004-5009, 2012.
63. D. Mitry and H. Zambarakji, "Recent trends in the management of maculopathy secondary to pathological myopia. Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 1, pp. 3-13, 2012.
64. R. Silva, "Myopicmaculopathy: a review. Ophthalmologica, vol. 228, no. 4, pp. 197-213, 2012.
65. H.M. Kang and H. J. Koh, "Ocular risk factors for recurrence of myopic choroidal neovascularization: long-Term follow-up study. Retina, vol. 33, no. 8, pp. 1613-1622, 2013.
66. T. Y. Wong, K. Ohno-Matsui, N. Leveziel, et al, "Myopic choroidal neovascularisation: current concepts and update on clinical management. British Journal of Ophthalmology, vol. 99, no. 3, pp. 289-296, 2015.
67. J. B. Gunther and M. M. Altaweel, "Bevacizumab (avastin) for the treatment of ocular disease. Survey of Ophthalmology, vol. 54, no. 3, pp. 372-400, 2009.
68. S. Wolf, V. J. Balciuniene, G. Laganovska, et al, "RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology, vol. 121, no. 3, pp. 682-692, 2014.
69. M. Gharbiya, R. Giustolisi, F. Allievi, et al, "Choroidal neovascularization in pathologicmyopia: intravitreal ranibizumab versus bevacizumab-A randomized controlled trial. American Journal of Ophthalmology, vol. 149, no. 3, pp. 458-464, 2010.
70. T. Y. Y. Lai, F. O. J. Luk, G. K. Y. Lee, and D. S. C. Lam, "Longterm outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye, vol. 26, no. 7, pp. 1004-1011, 2012.
71. M. Gliem, R. P. Finger, R. Fimmers, C. K. Brinkmann, F. G. Holz, and P. Charbel Issa, "Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina, vol. 33, no. 7, pp. 1300-1314, 2013.
72. K. JuliÁan, C. Terrada, C. Fardeau, et al, "Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-Term results. Acta Ophthalmologica, vol. 89, no. 2, pp. 179-184, 2011.
73. U. De Benedetto, M. Battaglia Parodi, K. A. Knutsson, et al, "Intravitreal bevacizumab for extrafoveal choroidal neovascularization after ocular trauma. Journal of Ocular Pharmacology andTherapeutics, vol. 28, no. 5, pp. 550-552, 2012.
74. S. Rizzo, F. Genovesi-Ebert, E. Bartolo, A. Vento, S. Miniaci, and G. Williams, "Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 6, pp. 837-842, 2008.
75. M. Modarres, H. Nazari, K. G. Falavarjani, M. Naseripour, M. Hashemi, and M. M. Parvaresh, "Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. European Journal of Ophthalmology, vol. 19, no. 5, pp. 848-852, 2009.
76. J. F. Arevalo, M. Maia, H. W. Flynn Jr, et al, "Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. British Journal of Ophthalmology, vol. 92, no. 2, pp. 213-216, 2008.
77. J. O. Mason III, P. A. Nixon, and M. F. White, "Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferativediabetic retinopathy, "American Journal ofOphthalmology, vol. 142, no. 4, pp. 685-688, 2006.
78. A.M. Minnella, C. M. Savastano, L. Ziccardi, et al, "Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmologica, vol. 86, no. 6, pp. 683-687, 2008.
79. S. Moradian, H. Ahmadieh, M. Malihi, M. Soheilian, M. H. Dehghan, and M. Azarmina, "Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 12, pp. 1699-1705, 2008.
80. H. A. Mintz-Hittner, K. A. Kennedy, and A. Z. Chuang, "Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity, "The New England Journal ofMedicine, vol. 364, no. 7, pp. 603-615, 2011.
81. S. J. Lim, M. I. Roh, and O.W. Kwon, "Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina, vol. 30, no. 1, pp. 100-106, 2010.
82. H. K. Seong, J. H. Bae, E. S. Kim, J. R. Han, W. H. Nam, and H. K. Kim, "Intravitreal bevacizumab to treat acute central serous chorioretinopathy: Short-Term effect. Ophthalmologica, vol. 223, no. 5, pp. 343-347, 2009.
83. B. George, W. J. Wirostko, T. B. Connor, and N. W. Choong, "Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. Journal of Thoracic Oncology, vol. 4, no. 5, pp. 661-662, 2009.
84. I. C. Kuo, J. A. Haller, R. Maffrand, R. H. Sambuelli, and V. E. Reviglio, "Regression of a subfoveal choroidalmetastasis of colorectal carcinoma after intravitreous bevacizumab treatment. JAMA Ophthalmology, vol. 126, no. 9, pp. 1311-1313, 2008.
85. H.-Y. Yao, C.-T. Horng, J.-T. Chen, and M.-L. Tsai, "Regression of choroidal metastasis secondary to breast carcinoma with adjuvant intravitreal injection of bevacizumab. Acta Ophthalmologica, vol. 88, no. 7, pp. e282-e283, 2010.
86. J. O. Mason III, M. A. Albert Jr, T. O. Persaud, and R. S. Vail, "Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina, vol. 27, no. 7, pp. 903-907, 2007.
87. B. R. Lima, L. R. Schoenfield, and A. D. Singh, "The impact of intravitreal bevacizumab therapy on choroidal melanoma. American Journal of Ophthalmology, vol. 151, no. 2, pp. 323.e2-328.e2, 2011.